Hbox Therapies, an Aachen, Germany-based MedTech startup that develops innovative treatment method for patients with lung failure, raised €2.3M in Seed funding.
Backers included TechVision Fonds (TVF), High-Tech Gründerfonds (HTGF) and business angel Prof. Dr. Peter Borges.The company intends to use the funds to develop and test a first prototype, marking an important step towards clinical trials.Founded by Dr. Peter Schlanstein, Niklas Steuer and Dr. Matthias Menne, HBOX Therapies has developed a technology solution (Hyperbaric Blood Oxygenation) that facilitates lung-protective treatment of respiratory patients. HBOX enables an exchange of carbon dioxide and oxygen that requires much smaller volumes of blood due to the increased pressure level. This makes the treatment less invasive and allows patients to be awake and breathing spontaneously during treatment. Additionally, the technology can be combined with established non-invasive or invasive mechanical ventilation (NIV or IMV) and used earlier than current ECMO procedures.23/02/2023
